Richard Aplenc, MD, PhD, MSCE

Dr. Aplenc is the Chief Clinical Research Officer at the Children’s Hospital of Philadelphia and the Section Chief for Hematologic Malignancies in the Division of Oncology. Dr. Aplenc’s research focus is in pediatric acute myeloid leukemia (AML) with ongoing translational research projects. He currently leads a child trial of a CD33 directed chimeric antigen receptor for children with relapsed and refractory acute myeloid leukemia. He also serves as the Vice-Chair of the Children’s Oncology Group AML Strategy Committee. Dr. Aplenc is a Professor of Pediatrics in the Department of Pediatrics with a secondary appointment in the Department of Biostatistics, Informatics, and Epidemiology.